English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Objective  To screen a library of potential therapeutic compounds for a woman with Lennox‐Gastaut syndrome due to a Y302C  GABRB3  (c.905A>G) mutation.    Methods  We compared the electrophysiological properties of cells with wild‐type or the pathogenic  GABRB3  mutation.    Results  Among 1320 compounds, multiple candidates enhanced  GABRB3  channel conductance in cell models. Vinpocetine, an alkaloid derived from the periwinkle plant with anti‐inflammatory properties and the ability to modulate sodium and channel channels, was the lead candidate based on efficacy and safety profile. Vinpocetine was administered as a dietary supplement over 6 months, reaching a dosage of 20 mg three times per day, and resulted in a sustained, dose‐dependent reduction in spike‐wave discharge frequency on electroencephalograms. Improved language and behavior were reported by family, and improvements in global impression of change surveys were observed by therapists blinded to intervention.    Significance  Vinpocetine has potential efficacy in treating patients with this mutation and possibly other  GABRB3  mutations or other forms of epilepsy. Additional studies on pharmacokinetics, potential drug interactions, and safety are needed.

Personalized medicine: Vinpocetine to reverse effects of GABRB3 mutation